The Covid-19 pandemic has accelerated the uptake of digital healthcare solutions and moved to personalized medicine in the UAE.

That innovative approach to engagement and tackling the challenges of today’s healthcare market has led Abu Dhabi to significantly improve equity in delivering healthcare services.

To provide personalized, precise, and preventive care, M42, a “tech-enabled” healthcare company, was launched by Abu Dhabi’s sovereign wealth fund Mubadala and artificial intelligence company G42. 

Designed to advance medical research and capabilities in the UAE capital, M42 is the result of a merger between the healthcare units of Mubadala and G42 that was first announced in October 2022. 

The M42 team, led by Hasan Jasem Al Nowais, group chief executive officer and managing director, said M42 would create a future in which dedicated healthcare professionals are empowered by the latest technology to optimize patient outcomes. 

“M42 also represents a platform for us to target international expansion and partner with global peers to solve the world’s most pressing healthcare challenges,” he added.

M42 will manage a wide portfolio of assets, including Amana Healthcare, Biogenix Labs, Danat Al Emarat, HealthPoint Hospital, the HealthPlus network of specialty centers, Moorfields Eye Hospital Abu Dhabi, and Imperial College London Diabetes Centre, among others.

Abu Dhabi has also launched a new funding program to support research and innovation to fight life-threatening diseases and a population-wide genetic library.